Targeting Transient Receptor Potential Melastatin‐2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer

Targeting Transient Receptor Potential Melastatin‐2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer

Abstract There is an urgent need to fully understand the biology of third generation EGFR‐tyrosine kinase inhibitors (EGFR‐TKIs), particularly osimertinib, and to develop mechanism‐driven strategies to manage their acquired resistance. Transient receptor potential melastatin‐2 (TRPM2) functions as a...

Full description

Bibliographic Details
Main Authors: Zhen Chen, Karin A. Vallega, Vijay K. Boda, Zihan Quan, Dongsheng Wang, Songqing Fan, Qiming Wang, Suresh S. Ramalingam, Wei Li, Shi‐Yong Sun
Format: Article
Language:English
Published: Wiley 2024-09-01
Series:Advanced Science
Subjects:
apoptosis
calcium
EGFR‐TKIs
lung cancer
osimertinib
TRPM2
Online Access:https://doi.org/10.1002/advs.202310126

Internet

https://doi.org/10.1002/advs.202310126

Similar Items